Jupiter Neurosciences, Inc. JUNS
Biotechnology: Pharmaceutical Preparations · IPO 2024 · data as of November 13, 2026
Jupiter Neurosciences, Inc. (JUNS) is a healthcare company listed in the US with a market value of about $2M. In fiscal year 2025 it had revenue of $21796 and net income of -$9M, a net margin of -39662.8%.
Its overall Stock Analiz score is 0.4 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -130%.
About Jupiter Neurosciences
Jupiter Neurosciences is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2024. It was profitable in 0 of the last 3 years in our data. It spends 9573% of revenue on research and development.
Score: 0.4 / 5
Checks passed
- Strong R&D investment or growth above 20%
- ROE above 15%
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
Valuation
Growth and quality
Financials, last 3 years
| Fiscal year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | $21796 | $0 | — |
| Net income | -$9M | -$2M | -$5M |
| Free cash flow | -$5M | — | -$480953 |
| EPS (diluted) | $-0.25 | $-0.08 | $-0.18 |
| Net margin | -39662.8% | — | — |
| ROIC | -201.8% | -57.6% | — |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Does Jupiter Neurosciences pay a dividend?
Not currently.
Is Jupiter Neurosciences a good stock to buy?
We do not give buy or sell advice. Jupiter Neurosciences scores 0.4 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.